Beijing Hebabiz Management Co Ltd

1. Through a dose escalation trial, observe the DLT and MTD of this product for patients with advanced solid tumors when the product is administered once a week by intravenous drip for 30 minutes, used for 2 consecutive weeks, and rested for 1 week, with each 3-week treatment cycle, so as to recommend a reasonable dosing regimen and basis for Phase II clinical studies; 2. Observe the pharmacokinetic (PK) characteristics of this product when administered intravenously. 3. Observe the frequency, duration and reversibility of adverse reactions of this product under the established dosing regimen. 4. Preliminary evaluation of the effectiveness of this product in patients with advanced solid tumors.